Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

The U.S. FDA has granted orphan drug designation to Eisai's (OTCPK:ESALF) Lenvima (lenvatinib) for esophageal cancer. The ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to AT-02 for the treatment of transthyretin-associated amyloidosis (ATTR). AT-02 is a fusion protein of humanized ...

Set to become compulsory Nov. 20, the regulation isn't likely to make pharma ads easier for consumers to comprehend, but ...

“We are pleased to have been granted orphan drug designation by the U.S. FDA for AT-02 in ATTR amyloidosis,” said Gregory Bell, M.D., Chief Medical Officer at Attralus. “Current approved therapies for ...

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

Former FDA director of investigations in the Chicago area, Ricki Chase, an expert in tracking counterfeit products, warns consumers to stay vigilant. "If you're buying a drug legitimately priced at ...

By converting immunologically 'cold' tumours into 'hot' ones, MB-108 may enhance the efficacy of the MB-101 CAR-T cell ...

Belief Biomed Inc.’s gene therapy drug BBM-D101 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Duchenne muscular dystrophy (DMD).